Azathioprine-induced sweet's syndrome in Crohn's disease
โ Scribed by Xavier Treton; Francisca Joly; Amaud Alves; Yves Panis; Yoram Bouhnik
- Publisher
- John Wiley and Sons
- Year
- 2008
- Tongue
- English
- Weight
- 82 KB
- Volume
- 14
- Category
- Article
- ISSN
- 1078-0998
No coin nor oath required. For personal study only.
โฆ Synopsis
FIGURE 1. Erythematous papules and pseudovesicles typical of Sweet's syndrome.
๐ SIMILAR VOLUMES
## Background: Thiopurines are considered first-line immunomodulators for the prevention of relapse in moderate to severe pediatric crohn's disease (cd). early introduction of thiopurines was shown in a pediatric trial to maintain steroid-free remission in 90% of patients for 18 months. in the pres
FIGURE 1. Disease progression. Kaplan-Meier analysis demonstrating disease progression over the follow-up period between the groups.
Schiff' first described a series of children with Crohn's disease in New York in 1945. He took care to exclude other diseases of the gastrointestinal tract with which it might clinically have been mistaken; these included infections by enteropathogenic bacteria and infestations with giardia and amoe